Literature DB >> 31012419

How Should Physicians Help Patients Understand Unknowns of Nanoparticle-Based Medicines?

Nancy M P King1, Christine E Bishop2.   

Abstract

When a patient wants to enroll in a clinical trial to gain early access to an apparently promising but unproven intervention, her physician should clarify differences between participating in research and receiving treatment to help her avoid therapeutic misconception, make a thoughtful decision, and consider relevant clinical and ethical details. These include a patient's disease and treatment experiences, needs, interests, values, the design and phase of the trial, and the nature of the intervention being studied. When an unproven intervention is a nanodrug, a physician's role is especially difficult, because though nanomedicine might offer real benefits, it can also pose unexpected or even unprecedented harms. Thus, a physician should help a patient explore possible outcomes while promoting realism, countering hype, and preserving hope.
© 2019 American Medical Association. All Rights Reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31012419     DOI: 10.1001/amajethics.2019.324

Source DB:  PubMed          Journal:  AMA J Ethics


  2 in total

Review 1.  Regenerative medicine clinical readiness.

Authors:  Satsuki Yamada; Atta Behfar; Andre Terzic
Journal:  Regen Med       Date:  2021-02-24       Impact factor: 3.806

2.  Should We Aim to Create a Perfect Healthy Utopia? Discussions of Ethical Issues Surrounding the World of Project Itoh's Harmony.

Authors:  Atsushi Asai; Taketoshi Okita; Motoki Ohnishi; Seiji Bito
Journal:  Sci Eng Ethics       Date:  2020-10-13       Impact factor: 3.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.